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Abstract
Background: Newer biological therapies for moderate-to-severe psoriasis are being used more
frequently, but unexpected effects may occur.
Case presentations: We present a group of 15 patients who developed inflammatory papules
while on efalizumab therapy (Raptiva, Genentech Inc, anti-CD11a). Immunohistochemistry showed
that there were increased CD11b+, CD11c+ and iNOS+ cells (myeloid leukocytes) in the papules,
with relatively few CD3+ T cells. While efalizumab caused a decreased expression of CD11a on T
cells, other circulating leukocytes from patients receiving this therapy often showed increased
CD11b and CD11c. In the setting of an additional stimulus such as skin trauma, this may predispose
to increased trafficking into the skin using these alternative β2 integrins. In addition, there may be
impaired immune synapse formation, limiting the development of these lesions to small papules.
There is little evidence for these papular lesions being "allergic" in nature as there are few
eosinophils on biopsy, and they respond to minimal or no therapy even if efalizumab is continued.
Conclusion: We hypothesize that these papules may represent a unique type of "mechanistic"
inflammatory reaction, seen only in the context of drug-induced CD11a blockade, and not during
the natural disease process.
Background
Newer biological agents have dramatically improved ther-
apeutic options for patients with psoriasis vulgaris requir-
ing systemic therapy. Curiously, despite our knowledge of
the target antigen of these biologic therapies, there may be
unknown or unexpected biological effects. Efalizumab
(Raptiva, Genentech Inc) is an FDA-approved treatment
for moderate-to-severe psoriasis vulgaris. Recent phase III
randomized, double-blind, placebo controlled trials have
shown that an excellent clinical result (Psoriasis Activity
and Severity Index, PASI 75) is obtained by week 12 in
approximately 30% of patients [1-3]. Efalizumab is a
humanized monoclonal antibody to CD11a, one of the
chains of the β2 integrin lymphocyte function-associated
antigen (LFA)-1. LFA-1 binds to intercellular adhesion
molecules (ICAMs), allowing leukocyte migration across
endothelial membranes during inflammation. Efalizu-
mab appears to block trafficking of leukocytes (particu-
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larly memory T cells) into sites of inflammation, leading
to a peripheral lymphocytosis [4]. There is also a decrease
in dendritic cells with efalizumab treatment [5]. However,
efalizumab may have additional effects as the LFA-1/
ICAM-1 interaction is also important in antigen presenta-
tion to T cells, and trafficking of T cells in the epidermis.
During clinical trials with efalizumab, we observed
patients who developed a variable number of small, scat-
tered erythematous papules during the treatment period.
The lesions were initially recognized by one of the authors
and were called "Papp's papules" by a number of derma-
tologists. These lesions resolved without additional treat-
ment or with mild-to-moderate topical corticosteroid
application, while efalizumab was continued. The rela-
tionship of these papular lesions to previously described
eruptions that develop while on efalizumab is unclear. An
advisory group of dermatologists described a clinical
eruption termed "localized mild breakthrough" during
the early stages of efalizumab therapy [6]. While these
lesions may be papules, they have not been characterized
by histology or for cellular composition by immunohisto-
chemistry.
We present a series of patients that developed these papu-
lar eruptions during efalizumab therapy, and characterize
this reaction histologically. To determine how leukocytes
might travel into the skin during efalizumab therapy, we
also analyzed integrin levels on circulating leukocytes. We
suggest that these lesions represent a unique drug-induced
"mechanistic" eruption that occurs during CD11a block-
ade, where leukocytes enter the skin using alternative
integrins, and the number and array of leukocytes in cuta-
neous lesions may be distinct from those in "normal"
inflammatory processes (when CD11a is functioning in
its usual manner). In addition, blockade of CD11c and
therefore LFA-1/ICAM-1 interaction in the immune syn-
apse may prevent initial and sustained T cell activation
and limit the development of these lesions to small
papules. Importantly, there is no evidence that this is a
conventional drug hypersensitivity or allergic process.
Case presentations
We collected biopsies from 15 patients receiving 1–2 mg/
kg/week efalizumab as part of several IRB-approved clini-
cal trials in North America. Informed consent was
obtained for participation in the trial by each center. Over-
all clinical status was determined (PASI score) and blood
taken for complete blood count where possible. Patients
were included if they had a lymphocytosis, which indi-
cated they had therapeutic levels of the drug. Details of the
patients are summarized in Table 1. Patients were not
included if their eruptions appeared after ceasing treat-
ment, which may be more indicative of disease relapse
from therapy withdrawal.
Clinical photographs were obtained for several patients
(Fig. 1), demonstrating a spectrum of presentation. There
were erythematous lesions with variable scale, some of
which appeared psoriasiform or occasionally pustular
(Fig. 1A). The lesions were often in unusual locations such
as the face or palms (Fig. 1B), scattered in flexural areas or
extensor surfaces. They were more often in new areas,
rather than areas with existing or previous psoriasis (Fig.
1C). At the time of the eruptions, all patients except one
had improving psoriasis, with PASI scores well below
starting levels. Central clearing of established plaques
could sometimes be seen as these papules were emerging
(Fig. 1C). Often, these papules developed toward the end
of the treatment period. Some patients reported pruritis,
while others were asymptomatic.
Table 1: Details of patients with erythematous papules while on efalizumab therapy
NO PASI baseline PASI D84 BX DAY PASI at biopsy
11 7 . 86D 7 0 4 . 2
2 12.2 3.4 D84 3.4
3 14.6 0.9 D42 0.9
4 12 4.8 D84 4.8
5 12.6 2.9 D28 9.5
62 3 . 6 1 2 . 4 D 8 4 1 2 . 4
7 16.3 9.8 D84 9.8
81 5 . 4 1 2 . 8 D 6 6 1 1 . 4
91 2 . 43D 2 8 9 . 4
10 28.1 15 D77 ~15
11 27 4.9 D53 2.4
12 8 6 D63 ND
13 12 ND D84 ND
14 20.5 13.8 D 28 33.8
15 60 30 D 28 ND
ND, not doneBMC Dermatology 2007, 7:2 http://www.biomedcentral.com/1471-5945/7/2
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Immunohistochemistry was performed on papular skin
biopsies to evaluate the leukocytic infiltrate of the lesions
(Fig. 2), as well as hematoxylin (Fisher) and eosin (Shan-
don, Pittsburgh) staining. The following antibodies were
used: keratin 16 (K16) (Sigma), CD3 (Becton Dickenson,
BD), CD11a (Immunotech), CD11b (BD), CD11c (BD
Clinical photographs from 3 patients with papular lesions while on efalizumab therapy, showing varied morphology of the  papules Figure 1
Clinical photographs from 3 patients with papular lesions while on efalizumab therapy, showing varied morphology of the 
papules. (A) Pustular lesions, (B) scaly lesions on the palms, and (C) erythematous lesions on the inner thigh (white arrow) 
adjacent to resolving plaque on the anterior thigh (black arrow).
A
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Pharmingen), iNOS (R&D Systems), elastase (BD), and
DC-LAMP (Immunotech). In most lesions, there was
some hyperkeratosis, occasionally alternating parakerato-
sis and orthokeratosis (only 1–2 cases), and there was epi-
dermal hyperplasia, dermal edema and a mononuclear
cell infiltrate. Where as normal epidermis is K16 negative,
all lesions were K16 positive, indicating epidermal regen-
erative hyperplasia. The most striking observation was the
large number of CD11b+ and/or CD11c+ leukocytes in
both the epidermis and dermis. INOS positivity mirrored
the CD11c+ cell infiltrate. In contrast to untreated psoria-
sis, the infiltrate was relatively T cell poor, with scant neu-
trophil elastase staining, and few CD14+  cells (not
shown). While the lesions share some features of psoria-
sis, there are notably fewer T cells (e.g. especially Patient
8), fewer neutrophils, less epidermal acanthosis, and less
consistent psoriasiform rete elongation. There was also a
notable lack of organized dermal infiltrates consisting of
T cells and dendritic cells.
CD11c+ and iNOS+ cells mark Tip-DCs, a new type of
inflammatory dendritic cell which is present in psoriatic
lesions [5]. We quantified the number of CD11c+ and
iNOS+ cells in the papular lesions (n = 14), and compared
these counts to normal skin (n = 10, n = 14 respectively)
and psoriasis (n = 69, n = 10 respectively). The normal
skin was obtained under an RU IRB-approved protocol
from healthy volunteers, after obtaining informed con-
sent. The CD11c+ psoriatic lesional counts were from a
large clinical trial with efalizumab, and this population
has been previously described [5]. The iNOS counts in
psoriasis lesional skin were also performed on pre-treat-
ment biopsies from IRB-approved clinical trials in our
department.
We found that there were significantly greater numbers of
CD11c+ and iNOS+ cells in the papular lesions compared
to normal skin (Fig. 3), but intermediate levels compared
to psoriasis. Cell counts in each group were analyzed by
ANOVA. The three conditions (normal skin, papules, and
psoriasis) showed differences in their mean values (p val-
ues for CD11c epidermis and dermis P < 0.0001, iNOS
epidermis P = 0.002, dermis P = 0.009). For post hoc test-
ing for multiplicity the Dunnett's T3 test was used.
CD11c+ cells were greater in the epidermis (mean 51 cells/
mm) and dermis (mean 136 cells/mm) of papular lesions
compared to normal skin (means 11 and 71 cells/mm
respectively) (P = 0.042 comparing epidermal CD11c+ cell
counts in papules to normal skin) (Fig. 3A). The CD11c+
cells were less than in the epidermis and dermis of psoria-
sis (mean 173 and 230 cells/mm respectively, (P < 0.0001
and P = 0.026 comparing papules and psoriasis epidermis
and dermis, respectively).
INOS staining showed a similar pattern of intermediate
numbers of positive cells in the papules, between normal
skin and psoriasis (Fig. 3B). In normal skin, there are no
iNOS positive cells in the epidermis, and dermal staining
intensity is relatively low. In the papules there were signif-
icantly greater numbers of iNOS positive cells in the epi-
dermis (20 cells/mm compared to 0 in the normal skin, P
= 0.026). In the dermis, there were similar numbers of
iNOS positive cells in papules compared to normal skin
(80 and 71 cells/mm respectively, but again lower than
psoriasis (126 cells/mm). Overall, there was infiltration of
CD11c+  cells into the dermis and epidermis of the
papules, and iNOS production was increased, especially
in the epidermis.
As part of an ongoing study of mechanistic effects of efal-
izumab on leukocytes in psoriasis patients, we have stud-
ied expression of β2 integrins on circulating granulocytes,
monocytes, and T cells. The following antibodies were
used for staining: CD11a FITC (Immunotech), CD11b PE
(BD) and CD11c PE (BD). Cells were acquired on the flow
cytometer (BD FACS Calibur) and gated on cell popula-
tions by size or CD3 positivity. Some patients in this
study, for example Patient 15 of this report, developed
papules during treatment. In this patient we found
increased expression of CD11b/CD18 on granulocytes
(Fig. 4A) co-incident with the development of papules on
the palms (Fig. 1B). CD11b was often increased on mono-
cytes by 2 weeks of efalizumab treatment (Fig. 4B),
although this was not restricted to patients with papules.
There was an expected decrease in CD11a on all cells with
saturation of the epitope by efalizumab in all leukocyte
populations, and the mean fluorescence intensity
decreased from baseline by greater than 50% [7]. CD11c
showed small and variable changes on monocytes and
granulocytes.
Conclusion
Integrins are cell-surface heterodimers that mediate cell-
cell and cell-matrix interactions [8]. The β2  group of
integrins comprise a variable α chain (CD11a, CD11b and
CD11c) and constant β2 (CD18) chain. CD11a/CD18,
also called LFA-1, binds ICAM-1, -2 and -3, and is present
on all leukocytes. As mentioned above, it has important
roles in leukocyte trafficking across the endothelium, anti-
gen presentation to T cells and immune synapse forma-
tion. These interactions are blocked by efalizumab.
CD11b/CD18 (Mac-1) binds ICAM-1 and iC3b. It is
present on myeloid cells, and some lymphocyte subsets.
Therefore it has some similar functions to LFA-1. CD11c/
CD18 (p150/95) binds fibrinogen and iC3b. CD11c is
present on myeloid cells, and is a well recognized marker
of myeloid dendritic cells and interstitial dendritic cells
[9,10]. The β1 family, also called very late antigens (VLA1-
6), comprise a series of molecules with a variable α chain,BMC Dermatology 2007, 7:2 http://www.biomedcentral.com/1471-5945/7/2
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Immunohistochemistry of papular lesions from three representative patients Figure 2
Immunohistochemistry of papular lesions from three representative patients. (A) Patient 5, (B) Patient 8, (C) Patient 10. Stain-
ing with H&E, keratin 16 (K16), CD3+ T cells, α chain of β2 integrins CD11a (blocked by efalizumab), CD11b, CD11c, iNOS, 
and neutrophil elastase. There are abundant CD11b, CD11c+, and iNOS+ cells in the lesions, with relatively less CD3+ lym-
phocytes.
Patient 5
H&E
K16
CD3
CD11a
CD11b
CD11c
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(CD49a-f) and constant β1 chain (CD29), and with a very
wide pattern of expression. The VLA integrins are also
involved in leukocyte trafficking.
Leukocyte emigration across the cutaneous vascular
endothelium involves a series of steps mediated by vari-
ous adhesion molecules in response to chemokine gradi-
ents: initial tethering of cells to the endothelium, loose
rolling along the vascular surface, firm adhesion to the
endothelium, and diapedesis between tightly apposing
endothelial cells [11]. The cells then traverse the endothe-
lial basal lamina and migrate through the extracellular
matrix. Integrins are important for several of these proc-
esses, including tethering (VLA-4), adhesion (LFA-1, Mac-
1, and VLA-4), and migration through the extracelluar
matrix (Mac-1).
It is possible that in the absence of LFA-1 other integrins
such as CD11b/CD18 or VLAs may allow leukocyte migra-
tion in response to inflammatory signals. For example, a
CD11a knockout mouse model demonstrated aggravated
Lyme carditis, [12]. Preformed CD11b is stored in leuko-
cytes and rapidly upregulated on activation [13], and leu-
kocyte CD11b upregulation has been seen in other
settings of inflammation [13-15].
However, changes in circulating leukocyte integrins alone
do not appear to be sufficient to induce these additional
lesions. An external trigger may also be required, such as
skin trauma, bacterial colonization, or microbial triggers,
and then these activated cells are able to enter the skin
using alternative integrins. Both CD11b+ and CD11c+ cells
may be playing a role in the development of these
papules. Increased numbers of CD11b+ cells have been
shown to be pathogenic in disease models such as
autoimmune uveitis or lung infection [16,17]. Recently,
we identified a population of CD11c+ myeloid dendritic
cells in psoriasis that produce TNF and iNOS, termed
"Tip-DCs" [5]. These Tip-DCs were decreased with efalizu-
mab therapy, in parallel with reduction in epidermal
thickness. However, if CD11b+ and CD11c+ cells are able
to traffic into the skin using alternative means, they may
then release inflammatory mediators contributing to
these papular lesions.
While the above discussion is focused on alternative traf-
ficking during CD11a blockade, the LFA-1/ICAM-1 inter-
action is also important for antigen presentation to T cells.
This interaction forms the initial contact zone in an
immune synapse between T cells and dendritic cells [18].
It is required to initiate T cell activation and may be crucial
for the formation of a sustained immune response. In the
dermis of mature psoriasis lesions, there are aggregates of
T cells and DC-LAMP+ mature dendritic cells creating sec-
ondary lymphoid structures [19] (Fig. 5A and 5B). The
LFA-1/ICAM-1 interaction may allow formation of these
aggregates, and in turn these T cell/dendritic cell aggre-
gates may be responsible for the perpetuation and chro-
nicity of psoriasis lesions. In these papules there is a
notable lack of T cells and dendritic cells forming these
organized dermal infiltrates. We found weak expression of
DC-LAMP on few cells in a popular lesion (Fig. 5C). In
this regard, these papular lesions could be considered an
early or abortive stage in the formation of a psoriatic
lesion. In the context of blockade of CD11a+, even if cells
can use alternative means to enter the skin, the lack of
CD11a prevents the LFA-1/ICAM interaction, and forma-
tion of dendritic cell/T cell aggregates, and thus the
papules cannot proceed to a "full-blown" psoriasis lesion.
Recently, we described two psoriasis patients who experi-
enced a flare of their disease while on efalizumab therapy
[7]. Treatment was ceased at the time of the systemic flare,
but was cautiously reintroduced at a later date, as there
was no other therapeutic option. This is in contrast to the
Cell counts for CD11c+ and iNOS+ leucocytes in normal skin,  papular lesions, and psoriasis Figure 3
Cell counts for CD11c+ and iNOS+ leucocytes in normal skin, 
papular lesions, and psoriasis. There are intermediate num-
bers of (A) CD11c+ and (B) iNOS+ cells in the papules com-
pared to normal skin and psoriasis. ANOVA with Dunnett's 
T3 test for multiplicity, * P < 0.05, *** P < 0.001.
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5% of patients who develop a worsening of their psoriasis
when therapy is ceased [20]. It is possible that both the
small lesions presented here, flare on ceasing therapy, and
the occasional systemic flare while on therapy may be part
of the same spectrum. However, the smaller scattered
lesions are clearly more common, and resolve without
treatment, and a more significant additional stimulus may
be required to cause a generalized eruption.
Importantly, there is no evidence of an allergic process in
the development of these papular lesions: few eosinophils
are seen on biopsy of these lesions, and they resolve with
minimal treatment even if efalizumab therapy is contin-
ued. If this were an allergic reaction, continued therapy
would cause worsening of the skin reaction, which is not
the case.
The histological differences between these papules and
psoriasis are that in the papular lesions there are reduced
T cells, neutrophils, CD14+ cells, lack of organized dermal
T cell and dendritic cell aggregates, and the epidermal
reaction has less acanthosis and psoriasiform rete elonga-
tion. We hypothesize that these lesions represent a unique
event, a type of "mechanistic" eruption, seen only in the
context of drug-induced CD11a blockade, and not during
a natural disease process. We hypothesize that these
lesions are unable to develop fully into psoriasis because
T cell entry across the cutaneous vasculature, and T cell
activation, are impaired during LFA-1/ICAM-1 blockade.
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